Clinical ResearchClinical TrialsThe Effect of Losartan Versus Atenolol on Cardiovascular Morbidity and Mortality in Patients With Hypertension Taking Aspirin: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
Clinical Trials
Under an Elsevier user license
open archive
Abbreviations and Acronyms
BP
blood pressure
CI
confidence interval
ECG
electrocardiogram
LIFE
Losartan Intervention For Endpoint reduction in hypertension
LVH
left ventricular hypertrophy
MI
myocardial infarction
RR
relative risk
Cited by (0)
Merck and Co., Inc., has supported the trial by an unrestricted grant and has reviewed the manuscript. Dr. Fossum has received speakers’ honoraria from Merck. Drs. Kjeldsen, Devereux, Julius, de Faire, Fyhrquist, Ibsen, Lederballe-Pedersen, Lindholm, Nieminen, Omvik, Oparil, Wedel, and Dahlöf are members of the LIFE Steering Committee and have received grant support from Merck and Co., Inc., the sponsor of the LIFE study. Drs. Moan, Snapinn, Edelman, and Kristianson are or have been employees of Merck and may own stock or stock options in the company. The presentation of data is the intellectual property of the LIFE Steering Committee.
Copyright © 2005 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.